Pharma
Alembic Pharma Secures USFDA Nod for Thyroid Drug in Major Global Healthcare Milestone
NE HEALTH BUREAU MUMBAI, MAY 22 In a significant advancement for India’s pharmaceutical industry and affordable global healthcare access, Alembic...
Read more
Strand Life Sciences Brings South Asia’s First Advanced Proteomics Platform to Accelerate Precision Healthcare
NE HEALTH BUREAU BENGALURU, MAY 20 In a major healthcare and biotechnology breakthrough for India and South Asia, Strand Life...
Read more
USFDA nod fuels global push: Alembic secures key Methotrexate approval
Final ANDA clearance strengthens oncology and immunology portfolio in US market Approval for multi-dose and single-dose vials of critical cancer...
Read more
Alembic scores big in US generics race with Dapagliflozin nod, eyes multi-billion dollar market
Alembic Pharmaceuticals Limited secures final USFDA approval for key diabetes therapy Generic version of Farxiga opens door to 180-day exclusivity...
Read more
Alembic Pharma secures USFDA nod for Paroxetine ER tablets, strengthens US Portfolio
Final approval for 12.5 mg extended-release tablets expands psychiatric care offerings Drug deemed equivalent to Paxil CR for multiple mental...
Read more
100% harvest of success: Indian Institute of Management Ahmedabad’s FABM cohort reaps full placements amid market churn
Total Triumph: Entire PGP-FABM batch secures placements; 45 students set to join firms by mid-2026 Sector Surge: Recruiters span agri-tech,...
Read more
Oat science meets baby care: Kenvue–IAP Bengaluru drive pushes evidence-based solutions for pediatric sensitive skin
Rising burden of atopic dermatitis in Indian children sparks urgent call for early intervention Kenvue India and IAP Bengaluru unite...
Read more
Gut power play: Eris Lifesciences bets big on microbiome boom with Velbiom buyout
₹50-crore acquisition of Velbiom Probiotics Pvt. Ltd.’s Rx portfolio signals aggressive push into next-gen gut science Strategic fit to turbocharge...
Read more
Game-changer in diabetes & obesity care: Sun Pharma launches affordable Semaglutide in India
‘Noveltreat’ & ‘Sematrinity’ aim to expand access to advanced GLP-1 therapy Weekly treatment costs slashed, making global-standard care more affordable...
Read more
₹220 per shot, a health revolution: Eris unlocks next-gen diabetes care for millions
Game-changing weekly semaglutide therapy launched at unprecedented affordability ‘SUNDAE’ aims to bring advanced GLP-1 treatment within reach of 70% of...
Read more
